10:19:51 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Amarantus BioScience Holdings, Inc. - "Burn Care 3.0: Tissue-Engineered Skin is Regenerative Medicine in Action"

2016-02-08 09:11 ET - News Release

NEW YORK, NY / ACCESSWIRE / February 8, 2016 / Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) today published a new blog post on The Chairman's Blog, written by Dr. David A. Ahrenholz. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog, Dr. Ahrenholz highlights his article "Burn Care 3.0: Tissue-Engineered Skin is Regenerative Medicine in Action" originally published on PlasticSurgeryPractice.com. Dr. Ahrenholz discusses the current state of severe burn treatment options, noting that there has not been a commercially available solution that functions like an autologous skin graft until now. He expands on Amarantus BioScience's Engineered Skin Substitute (ESS), and its potential for the treatment of large burns. Highlighting that unlike the current standard of care, ESS reduces both the patient's suffering and high risk of infection. Read the full blog post from Dr. Ahrenholz on TheChairmansBlog.com http://www.thechairmansblog.com/amarantus-bioscience/david-ahrenholz/burn-care-3-0-tissue-engineered-skin-is-regenerative-medicine-in-action/

Original Aricle Source: http://www.plasticsurgerypractice.com/2015/11/burn-care-3-0-tissue-engineered-skin-regenerative-medicine-action/

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

© 2024 Canjex Publishing Ltd. All rights reserved.